Colorectal cancer (BRAF V600E-mutant mCRC) MedDRA version: 21.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Trade Name: BRAFTOVI®
Product Name: Encorafenib
Product Code: PF-07263896
Pharmaceutical Form: Capsule
INN or Proposed INN: ENCORAFENIB
CAS Number: 1269440-17-6
Current Sponsor code: PF-07263896
Conce
Sponsors
Pfizer Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Molecular Prescreening Inclusion Criteria Age and Sex: 1. SLI: Male or female participants age =18 years at the time of informed consent. Phase 3 and Cohort 3: Male or female participants age =16 years at the time of informed consent/assent in all countries where permitted. In countries or sites where enrollment of adolescents is not permitted (eg, Germany), male or female participants age =18 years at the time of informed consent. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants. Weight: 2. Body weight =40 kg. Type of Participant and Disease Characteristics: 3. Participants with histologically or cytologically confirmed colorectal adenocarcinoma. 4. Participants with evidence of Stage IV metastatic disease. Note: Patients with oligometastatic disease previously treated with curative intent are eligible to participate in the study as long as they have baseline measurable disease per RECIST 1.1. Oligometastatic colorectal cancer is characterized by a limited metastatic spread of disease. Oligometastatic disease is defined as the involvement of up to 3 sites with 5 or sometimes more metastases that for their anatomic localization is amenable to local therapies, thus rendering the patient free of disease. 5. Able to provide a sufficient amount of representative tumor specimen for central testing of BRAF V600E mutation status and tumor tissue assessment Note: Tumor sample can be archival or de novo (newly collected fixed biopsy sample) and must be in an FFPE block, or provide a minimum of 15 unstained slides of analyzable tissue. This tissue specimen should be obtained from a biopsy or surgery that was performed within 2 years prior to study enrollment. Participants with fewer than the required number of slides with analyzable tissue may be considered eligible if the Sponsor determines that the slides are sufficient for central testing. Informed Consent/Assent: 6. Capable of giving signed informed consent/assent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Note: Participants =16 years old that are under guardianship may participate with the consent of their legally authorized guardian if permitted by local regulations. When appropriate, adolescent participants will be included in all discussions (see Section 10.1.3). 5.1.2. Screening Inclusion Criteria Type of Participant and Disease Characteristics: 7. Participants who have met all Molecular Prescreening inclusion criteria. 8. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 9. Presence of a BRAF V600E mutation in tumor tissue or blood (eg, ctDNA genetic testing). The following are acceptable: a. Local laboratory assay (PCR or NGS-based only) performed at any time prior to Screening using either tumor tissue or blood. b. Central laboratory assay performed during the Screening period using tumor tissue alone (not blood). Note: For participants enrolled on the basis of a local BRAF mutation assay, tumor samples must be submitted to the central laboratory for BRAF testing as soon as possible following signing of the ICD. The BRAF status must be confirmed no later than 30 days following first dose of study intervention. 10. The Investigator must obtain prior to Cycle 1 Day 1 (SLI) or date of randomization (Phase 3 and Cohort 3) ade
Exclusion criteria
Exclusion criteria: Molecular Prescreening Exclusion Criteria Medical Conditions: 1. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study. 2. Presence of acute or chronic pancreatitis. 3. Leptomeningeal disease. 4. History of chronic inflammatory bowel disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) =12 months prior to randomization. 5. Known DPD deficiency; refer to local fluorouracil or capecitabine label or local clinical guidances, for DPD status recommendation prior to starting treatment. 6. Gilbert’s syndrome or known homozygous UGT1A1*28/*28 or UGT1A1*6/*6 genotypes or double heterozygous UGT1A1*6/*28 genotype: a. SLI: Participants with documented Gilbert’s syndrome or known homozygous UGT1A1*28/*28 or UGT1A1*6/*6 genotypes or double heterozygous UGT1A1*6/*28 genotype will be excluded from Cohort 1 (EC + FOLFIRI) of the SLI. b. b.Phase III: Participants with documented Gilbert's syndrome or known homozygous UGT1A1*28/*28 or UGT1A1*6/*6 genotypes or double heterozygous UGT1A1*6/*28 genotype may be enrolled, but may not receive FOLFOXIRI if randomized to the Control Arm. c. Cohort 3: Participants with documented Gilbert's syndrome or known homozygous UGT1A1*28/*28 or UGT1A1*6/*6 genotypes or double heterozygous UGT1A1*6/*28 genotype will be excluded from Cohort 3 Arm D and Arm E (EC + FOLFIRI and FOLFIRI ± bevacizumab). Other Exclusions: 7. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. 8. Colorectal adenocarcinoma that is RAS mutant or for which RAS mutation status is unknown. 9.9. Locally confirmed dMMR or MSI-H colorectal carcinoma or unknown MSI/MMR status. If participant is locally confirmed dMMR or MSI-H and unable to receive immune checkpoint inhibitors due to a pre existing medical condition, they may be enrolled. 5.2.2. Screening Exclusion Criteria Medical Conditions: 10. Impaired gastrointestinal function (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, small bowel resection) or disease which may significantly alter the absorption of oral study intervention or recent changes in bowel function suggesting current or impending bowel obstruction. 11. Clinically significant cardiovascular diseases, including any of the following: a. History of acute myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft, coronary angioplasty or stenting) =6 months prior to randomization; b. Congestive heart failure requiring treatment (New York Heart Association Class II and above); c. Recent history (within 1 year prior to randomization) or presence of clinically significant cardiac arrhythmias (including uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia); d. History of thromboembolic or cerebrovascular events =12 weeks prior to randomization. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive) deep vein thrombosis or pulmonary emboli. Note: Participants with either deep vein thrombosis or pulmonary emboli that do not result in hemodynamic instability are allowed to
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Safety Lead-In: To determine the safety and tolerability of EC + mFOLFOX6 and EC + FOLFIRI Phase 3: • To compare the efficacy of EC + mFOLFOX6 (Arm B) vs SOC (Control Arm [Arm C]) as measured by PFS and by ORR Cohort 3: • To compare the efficacy of EC + FOLFIRI (Arm D) vs FOLFIRI with or without bevacizumab (Control Arm [Arm E]) as measured by ORR;Secondary Objective: Safety Lead-In: Assess the overall safety and tolerability of EC + mFOLFOX6 and EC + FOLFIRI Estimate the efficacy of EC + mFOLFOX6 and EC + FOLFIRI Estimate the efficacy of EC + mFOLFOX6 and EC + FOLFIRI Characterize the PK of encorafenib, irinotecan, oxaliplatin and relevant metabolite Assess drug-drug interaction of encorafenib with irinotecan or oxaliplatin Ph3 Further compare the efficacy of Arm B vs the Control Arm as measured by OS Further evaluate efficacy of Arm B vs the Control Arm as measured by ORR, DOR, PFS, PFS2 and TTR Evaluate efficacy of EC (Arm A) vs the Control Arm as measured by ORR, DOR, PFS, PFS2, TTR and OS Evaluate efficacy of Arm A vs Arm B as measured by OS, PFS, PFS2, ORR, DOR and TTR Determine the safety and tolerability of EC Determine the safety and tolerability of EC + mFOLFOX6 Cohort 3: Further compare the efficacy of Arm D vs Arm E as measured by PFS;Primary end point(s): Safety Lead-In: Incidence of DLTs Phase 3: • PFS by BICR, defined as the time from the date of randomization to the earliest documented disease progression per RECIST v1.1, or death due to any cause • ORR by BICR Cohort 3: • ORR by BICR;Timepoint(s) of evaluation of this end point: Safety Lead-In: The DLT evaluation period is the first 28 days after the first dose of study intervention. Phase 3: PFS and ORR: 42 to 49 days from the date of randomization then Q6W (±7D) for the first 18 months after the date of randomization then Q8W (±7D) thereafter or until BICR-confirmed PD (regardless of new anticancer therapy), withdrawal of consent/assent, participant is lost to followup, d | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Safety Lead-In: Incidence and severity of AEs graded according to the NCI CTCAE v4.03 and changes in clinical laboratory parameters, vital signs and ECGs Incidence of dose interruptions, dose modifications and discontinuations due to AEs ORR by Investigator, defined as the proportion of participants who have achieved a confirmed BOR (CR or PR) per RECIST v1.1 DOR by Investigator, defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST v1.1, or death due to any cause PFS by Investigator, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause TTR by Investigator, defined as the time from first dose to first radiographic evidence of response (CR or PR) per RECIST v1.1 OS defined as the time from the first dose to death due to any cause PK parameters of encorafenib, irinotecan, oxaliplatin and relevant metabolites Changes in exposures of irinotecan and its metabolite (SN-38) on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 1 (EC + FOLFIRI) Changes in exposures of oxaliplatin on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 2 (EC + mFOLFOX6) Phase 3: OS, defined as the time from the date of randomization to death due to any cause ORR by Investigator ORR by BICR (Arm A vs Control Arm, Arm A vs Arm B) DOR by BICR and by Investigator PFS by BICR (Arm A vs Control Arm, Arm A vs Arm B) OS (Arm A vs Control Arm, Arm A vs Arm B) PFS by Investigator TTR (by BICR and by Investigator), defined as the time from the date of randomization to first radiographic evidence of response (CR or PR) per RECIST v1.1 PFS2, defined as the time from the date of randomization to the date of discontinuation of next-line treatment after first objective PD by investigator assessment, the second objective disease progression, or death from any cause, whichever occurs first Incidence and severity of AEs g | — |
Countries
Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Czech Republic, Denmark, Finland, France, Germany, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Contacts
Public ContactClinical Trials.gov Call Centre
Pfizer Inc.
Outcome results
None listed